Histone deacetylase inhibitors reinforce the phenotypical markers of breast epithelial or mesenchymal cancer cells but inhibit their migratory properties

INTRODUCTION: Histone deacetylase inhibitors (HDIs) are a group of compounds that exhibit anticancer activity, but their significance and usefulness in breast cancer (BC) treatment are still controversial. The ability of cancer cells to invade and migrate is augmented by the acquisition of a mesench...

Descripción completa

Detalles Bibliográficos
Autores principales: Wawruszak, Anna, Gumbarewicz, Ewelina, Okon, Estera, Jeleniewicz, Witold, Czapinski, Jakub, Halasa, Marta, Okla, Karolina, Smok-Kalwat, Jolanta, Bocian, Artur, Rivero-Muller, Adolfo, Stepulak, Andrzej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6750858/
https://www.ncbi.nlm.nih.gov/pubmed/31571991
http://dx.doi.org/10.2147/CMAR.S210029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6750858/
https://www.ncbi.nlm.nih.gov/pubmed/31571991
http://dx.doi.org/10.2147/CMAR.S210029

Ejemplares similares